Maze Therapeutics (MAZE) Other Accumulated Expenses (2024 - 2026)

Maze Therapeutics (MAZE) has 3 years of Other Accumulated Expenses data on file, last reported at $438000.0 in Q1 2026.

• For the quarter ending Q1 2026, Other Accumulated Expenses changed N/A year-over-year to $438000.0; the trailing twelve-month figure through Mar 2026 stood at $438000.0 (changed N/A YoY), and the FY2025 full-year result was $149000.0, down 75.89% from the prior year.
• Other Accumulated Expenses grew to $438000.0 in Q1 2026, from $149000.0 in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $5.1 million in Q3 2025 to a low of $53000.0 in Q2 2025.
• A 3-year average of $1.3 million and a median of $438000.0 in 2026 frame the typical range for Other Accumulated Expenses.
• Peak annual rise in Other Accumulated Expenses reached 75.89% in 2025, while the deepest fall reached 75.89% in 2025.
• Tracing MAZE's Other Accumulated Expenses over 3 years: stood at $618000.0 in 2024, then plunged by 75.89% to $149000.0 in 2025, then soared by 193.96% to $438000.0 in 2026.
• Business Quant data shows MAZE's Other Accumulated Expenses at $438000.0 in Q1 2026, $149000.0 in Q4 2025, and $5.1 million in Q3 2025.